Daily Cardiology Research Analysis
Analyzed 225 papers and selected 3 impactful papers.
Summary
Three high-impact cardiology studies stood out today: an individual patient data meta-analysis clarified prognostic differences across Universal Definition categories of myocardial injury and infarction; a nationwide target trial emulation showed no overall survival advantage of CTO PCI over medical therapy in stable CAD, emphasizing the importance of procedural success; and human plaque mapping identified fibroblast-like smooth muscle cell–derived populations accumulating around necrotic cores, linking mesenchymal transitions to late atherogenesis.
Research Themes
- Risk stratification across myocardial injury and infarction phenotypes
- Comparative effectiveness of CTO PCI versus medical therapy using target trial emulation
- Human coronary plaque biology: smooth muscle–derived fibroblast-like cells and necrotic core formation
Selected Articles
1. Cardiovascular Risk Across Myocardial Injury and Infarction Categories Using the Universal Definition: An Individual Patient-Level Data Meta-Analysis.
Across 120,734 patients adjudicated by the Universal Definition, all categories of myocardial injury/infarction showed substantially elevated MACE versus those without injury. Type 2 MI had a similar MACE rate to type 1 MI but a markedly higher non-cardiovascular death rate, highlighting competing risk that attenuates apparent cardiovascular risk in type 2 MI.
Impact: This large IPD meta-analysis resolves uncertainty regarding the prognostic significance of myocardial injury and type 2 MI, informing triage, follow-up, and trial design that account for competing risks.
Clinical Implications: Patients with myocardial injury and MI require structured cardiovascular risk management, but type 2 MI needs holistic care given high non-cardiovascular mortality; competing-risk aware endpoints and follow-up strategies are warranted.
Key Findings
- All myocardial injury/infarction categories had higher MACE than no injury; type 1 MI and type 2 MI rates were 55.2 and 51.7 per 1,000 patient-years, respectively.
- Type 2 MI had substantially higher non-cardiovascular mortality (60.1 per 1,000 patient-years) than type 1 MI (25.7 per 1,000 patient-years).
- Compared with no injury, the subdistribution hazard for MACE was markedly elevated (e.g., 4.82; 95% CI 3.55–6.57), underscoring prognostic relevance across categories.
Methodological Strengths
- Individual patient-level data meta-analysis across multiple cohorts with competing-risk modeling
- Prospective study inclusion using standardized Universal Definition adjudication; PROSPERO-registered
Limitations
- Heterogeneity across cohorts and potential residual confounding inherent to observational data
- Some incomplete reporting and variability in diagnostic workup over time and settings
Future Directions: Design trials and care pathways that integrate competing-risk aware endpoints, refine type 2 MI phenotyping, and test comprehensive multimorbidity management to reduce non-cardiovascular mortality.
BACKGROUND: The Universal Definition classifies myocardial infarction (MI) by etiology, but its prognostic implications are uncertain. OBJECTIVES: The goal was to compare the rate and risk of recurrent MI or cardiovascular death among patients with myocardial injury and infarction classified according to the Universal Definition. METHODS: A systematic search of MEDLINE, EMBASE, Central, and Web of Science from January 1, 2007 to July 1, 2025 was performed to identify prospective studies where cardiac troponin was measured for suspected acute coronary syndrome, diagnoses were adjudicated using the Universal Definition, and both MI and cause-specific mortality were reported at a minimum of 1 year. Subdistribution HRs were derived to account for the competing risk of noncardiovascular death. Meta-analysis was performed with random-effects models. The primary outcome was major adverse cardiovascular events (MACE), defined as MI or cardiovascular death. The secondary outcome was noncardiovascular death. RESULTS: We identified 17 studies of 9 cohorts from 9 countries, with individual patient-level data available in 8 cohorts. Among 120,734 patients (median age: 61.0 years; 45.8% women), type 1 MI occurred in 9.4% (n = 11,298), type 2 MI in 3.0% (n = 3,609), acute myocardial injury in 4.9% (n = 5,864), and chronic myocardial injury in 4.7% (n = 5,625). In patients with type 1 and type 2 MI, the MACE rate was 55.2 and 51.7 per 1,000 patient-years and the noncardiovascular death rate was 25.7 and 60.1 per 1,000 patient-years, respectively. Compared with those without myocardial injury, the risk of MACE (subdistribution HR) was 4.82 (95% CI: 3.55-6.57; I
2. Fibroblast-like cells accumulate late in human coronary atherosclerosis contributing to necrotic core formation.
Using scRNA-seq–validated multiplex immunostaining and ML-assisted plaque phenotyping in human coronaries, the study shows that fibroblast-like, lumican-expressing mesenchymal cells lacking contractile proteins expand at the fibroatheroma stage and cluster around necrotic cores, accounting for a large fraction of apoptotic cells. Osteoprotegerin bound to calcifications, but mesenchymal subtypes did not specifically co-localize with fibrosis/calcification.
Impact: Provides human-tissue evidence refining the cellular ecology of advanced plaques, linking SMC phenotypic modulation to necrotic core development—a potential pivot for stabilizing-plaques therapies.
Clinical Implications: Targets modulating SMC-to-fibroblast-like transitions or their survival near the necrotic core may help stabilize vulnerable plaques; histologic signatures could inform imaging biomarkers of plaque risk.
Key Findings
- Fibroblast-like, lumican-expressing mesenchymal cells lacking contractile proteins become prominent only at the fibroatheroma stage.
- These cells localize around the necrotic core and account for 38–54% of apoptotic cells with determined origin.
- Secreted osteoprotegerin was bound to calcium deposits, whereas mesenchymal subtypes did not preferentially co-localize with fibrosis or calcification.
Methodological Strengths
- scRNA-seq–validated marker panels with multiplex immunostaining across defined plaque stages
- Machine learning–assisted whole-plaque phenotyping; inclusion of human coronary and carotid tissues
Limitations
- Cross-sectional human tissue analysis precludes causal inference over time
- Sample size and reliance on autopsy/endarterectomy specimens may limit generalizability
Future Directions: Longitudinal human imaging–pathology correlation and interventional studies targeting SMC phenotypic transitions to test effects on necrotic core growth and plaque stability.
AIMS: Proliferation of arterial smooth muscle cells (SMCs) and their modulation to alternative mesenchymal phenotypes is central to atherosclerotic lesion growth. It has been studied extensively in mouse models, but a detailed analysis of when and where different mesenchymal cell types accumulate in human atherosclerosis is lacking. This study mapped mesenchymal cell populations during the progression of human coronary atherosclerosis and explored their associations with disease processes in human carotid plaques. METHODS AND RESULTS: Multiplex immunostaining protocols based on single-cell RNA sequencing-validated markers were established to detect SMCs, putatively SMC-derived mesenchymal cell subsets expressing osteoprotegerin or lumican, and macrophages in sections of left anterior descending arteries from forensic autopsies. The material comprised 44 arterial segments from 38 individuals, spanning normal intima, adaptive intimal thickening, pathological intimal thickening, and fibroatheroma. Parallel analysis of carotid endarterectomy samples allowed examination of mesenchymal cell involvement in fibrosis, calcification, and apoptosis. Validated machine learning-assisted cell classification was used to phenotype entire plaques at high microscopic resolution.The combined mesenchymal cell population constituted the majority of plaque cells at all plaque stages. Cells co-expressing contractile and mesenchymal cell markers were present in normal human coronary arteries, but mesenchymal cells lacking contractile protein expression became prominent only at the fibroatheroma stage, where fibroblast-like lumican-expressing cells localized preferentially around the necrotic core. The mesenchymal cell subtypes showed no preferential co-localization with areas of fibrosis or calcification; however, secreted osteoprotegerin was found bound to calcium deposits. Fibroblast-like, lumican-expressing cells accounted for 38-54% of all apoptotic cells for which a cell origin could be determined. CONCLUSIONS: Putative SMC-derived mesenchymal cells without contractile protein expression expand at the fibroatheroma stage of coronary atherosclerosis. Fibroblast-like cells localize around the necrotic core region and account for many apoptotic cells in plaques, suggesting a role in necrotic core development.
3. CTO PCI vs. medical therapy in stable CAD: real-world outcomes from a target trial emulation of SCAAR registry data.
In a nationwide target trial emulation of 7,813 CTO patients, adjusted analyses found no overall survival benefit for CTO PCI versus medical therapy, though successful CTO PCI was associated with improved survival. The results emphasize procedural success and careful selection rather than routine CTO PCI for survival gain.
Impact: Provides high-quality real-world comparative effectiveness using modern causal inference, challenging routine CTO PCI for survival and guiding patient selection and operator quality metrics.
Clinical Implications: Reserve CTO PCI for patients with symptoms/ischemia where success is likely; emphasize procedural planning, operator expertise, and shared decision-making about benefits beyond mortality (symptoms, quality of life).
Key Findings
- After IPTW and IV adjustment, CTO PCI showed no significant overall survival advantage versus medical therapy (IPTW HR 0.94; IV HR 1.00).
- Successful CTO PCI was associated with improved survival (HR 0.74), whereas unsuccessful procedures were not (HR 1.08).
- Subgroup analyses showed no consistent benefit; a modest survival signal was observed in non-diabetic patients.
Methodological Strengths
- Target trial emulation with time-dependent exposure modeling and IPTW plus instrumental variable analysis
- Nationwide registry with long follow-up (median 5.08 years) and large sample size
Limitations
- Residual confounding cannot be excluded; procedural success may reflect unmeasured patient and operator factors
- Outcomes focused on mortality; symptom relief and quality-of-life benefits were not primary endpoints
Future Directions: Prospective trials and registries integrating symptom/QOL outcomes, ischemia burden, and operator metrics to refine CTO PCI indications and optimize success rates.
BACKGROUND: The prognostic benefit of percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) in stable coronary artery disease (CAD) remains uncertain. OBJECTIVES: To evaluate long-term survival following CTO PCI compared with medical therapy (MT) using target trial emulation and a nationwide real-world registry. METHODS: We included 7813 patients with stable CAD and a documented CTO from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) between 2015 and 2024. CTO PCI was modeled as a time-dependent exposure. The primary outcome was all-cause mortality. We used inverse probability of treatment weighting (IPTW), time-dependent Cox regression, and instrumental variable (IV) analysis to adjust for confounding. RESULTS: Over a median follow-up of 5.08 years, 1253 deaths occurred. While unadjusted survival favored CTO PCI (HR 0.74; 95% CI, 0.64-0.86; p < 0.001), IPTW and IV adjustment showed no significant reduction in mortality compared with MT (IPTW HR 0.94; 95% CI, 0.80-1.10; p = 0.41; IV HR 1.00; 95% CI, 0.71-1.40; p = 0.999). Successful CTO PCI was associated with improved survival (HR 0.74; 95% CI, 0.62-0.87), whereas unsuccessful procedures were not (HR 1.08; 95% CI, 0.79-1.47). Subgroup analyses showed no consistent benefit, although a modest survival advantage was observed in non-diabetic patients. CONCLUSIONS: In this large nationwide study using target trial emulation, CTO PCI was not associated with improved overall survival compared with MT. Only successful procedures conferred a benefit, highlighting the importance of procedural success and patient selection in CTO revascularization strategies.